Reuters logo
BRIEF-Neuralstem reports last subject out in phase 2 trial of NSI-189 for major depressive disorder
May 17, 2017 / 8:48 PM / 4 months ago

BRIEF-Neuralstem reports last subject out in phase 2 trial of NSI-189 for major depressive disorder

May 17 (Reuters) - Neuralstem Inc

* Neuralstem reports last subject out in phase 2 trial of NSI-189 for major depressive disorder Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below